We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Fate of FDA Orphan Drug Exclusivity Still in the Balance, Agency Official Says
Fate of FDA Orphan Drug Exclusivity Still in the Balance, Agency Official Says
After years of legal wrangling, the FDA is still grappling with the issue of how exactly to define “exclusivity” in its orphan drug program, according to one senior agency official who says legislative action may be needed to end the debate.